Distribuzione geografica
Continente #
NA - Nord America 10755
EU - Europa 6579
AS - Asia 2789
AF - Africa 413
SA - Sud America 23
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 7
Totale 20577
Nazione #
US - Stati Uniti d'America 10719
GB - Regno Unito 2713
SE - Svezia 1162
CN - Cina 1157
VN - Vietnam 1032
IT - Italia 591
DE - Germania 510
IN - India 483
UA - Ucraina 471
RU - Federazione Russa 339
FR - Francia 332
ZA - Sudafrica 211
EE - Estonia 205
TG - Togo 163
GR - Grecia 92
CA - Canada 36
SC - Seychelles 35
BE - Belgio 33
IR - Iran 32
CH - Svizzera 23
JP - Giappone 22
PL - Polonia 20
LB - Libano 17
NL - Olanda 15
BR - Brasile 12
KR - Corea 12
AU - Australia 11
CL - Cile 9
FI - Finlandia 9
HR - Croazia 9
UZ - Uzbekistan 9
RO - Romania 8
CZ - Repubblica Ceca 7
ES - Italia 6
AT - Austria 5
BG - Bulgaria 5
DK - Danimarca 5
PT - Portogallo 5
A2 - ???statistics.table.value.countryCode.A2??? 4
MK - Macedonia 4
SG - Singapore 4
BD - Bangladesh 3
EG - Egitto 3
EU - Europa 3
HK - Hong Kong 3
EC - Ecuador 2
IE - Irlanda 2
MY - Malesia 2
NO - Norvegia 2
PH - Filippine 2
RS - Serbia 2
TR - Turchia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BY - Bielorussia 1
GE - Georgia 1
ID - Indonesia 1
IL - Israele 1
IQ - Iraq 1
MD - Moldavia 1
NG - Nigeria 1
SA - Arabia Saudita 1
SI - Slovenia 1
SM - San Marino 1
TH - Thailandia 1
Totale 20577
Città #
Southend 2521
Fairfield 1992
Houston 980
Woodbridge 947
Seattle 856
Ashburn 831
Wilmington 794
Dong Ket 740
Ann Arbor 665
Cambridge 662
Princeton 592
Chandler 460
Jacksonville 276
Westminster 270
Nanjing 248
Padova 216
Lomé 163
Berlin 150
Bologna 128
Jinan 124
San Diego 122
Saint Petersburg 119
Shenyang 116
Beijing 80
Nanchang 69
Changsha 67
Hebei 66
Tianjin 63
Redmond 57
Medford 55
Dearborn 49
Jiaxing 45
Norwalk 44
Falls Church 42
Des Moines 39
Mahé 35
Milan 33
Ningbo 33
Brussels 32
Guangzhou 27
Haikou 26
Hangzhou 26
Redwood City 26
Zhengzhou 23
Tokyo 22
Lanzhou 20
Taizhou 20
Toronto 19
Frankfurt Am Main 17
Kunming 16
Athens 14
Buffalo 13
Costa Mesa 13
Frankfurt am Main 13
Andover 12
Leawood 12
North York 12
San Venanzo 12
Fuzhou 11
San Francisco 11
Taiyuan 11
Verona 11
Ardabil 10
Grafing 10
Phoenix 10
Helsinki 9
Sacramento 9
São Paulo 9
Zanjan 9
Kuban 8
Monmouth Junction 8
Dolo 7
Groningen 7
Hefei 7
Moscow 7
Lausanne 6
Orange 6
Reggio Nell'emilia 6
Ulan-ude 6
Changchun 5
Den Haag 5
Fremont 5
Henderson 5
Kiev 5
Las Vegas 5
London 5
Plauen 5
Provo 5
Saint Louis 5
Stockholm 5
Benevento 4
Hanover 4
Singapore 4
Aachen 3
Amsterdam 3
Boardman 3
Castelnuovo Don Bosco 3
Chengdu 3
Genzano Di Roma 3
Imola 3
Totale 15390
Nome #
Adaptive response in Hepatitis B virus infection 172
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 163
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography 162
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 156
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 153
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 143
Clinical and serological profile of primary biliary cirrhosis in men. 135
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 133
Alcohol and viral hepatitis: a mini-review. 133
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 129
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 128
Genetic variability of hepatitis C virus in HBV/HCV co-infection and HCV single-infection. 127
Treating hepatitis C in the elderly: the future is near? 127
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 127
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 125
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. 125
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. 125
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 124
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 124
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 123
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 123
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 119
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 117
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned. 116
Anti-synthetase syndrome with lung involvement associated with primary biliary cirrhosis: A case report 115
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 113
Assessment of liver fibrosis in trnsplant recipients with recurrent HCV infection: Usefulness of transient elastography. 113
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 112
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B 112
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 112
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 112
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 111
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 110
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 107
null 107
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients. 107
null 107
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 106
Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. 106
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 105
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 104
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. 104
null 103
Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients 102
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection 102
Chronic hepatitis B: Are we close to a cure? 102
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. 101
Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. 100
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 99
Vitamins in the treatment of chronic viral hepatitis. 99
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 98
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. 98
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis 98
null 98
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 98
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury 98
Low replication and variability of HBV pre-core in concomitant infection with hepatitis B and hepatitis C viruses 97
Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report 97
Virological analysis, genotypes and mutational patterns of the HBV pre-core/core gene in HBV/HCV-related hepatocellular carcinoma. 97
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients. 96
null 96
Point quantification elastography in the evaluation of liver elasticity in healthy volunteers: a reliability study based on operator expertise 96
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 96
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 95
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. 94
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 94
Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. 94
Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease 94
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 94
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 93
Liver transplantation for patients with alcoholic liver disease: an open question 93
Bipolar and related disorders induced by sodium 4-phenylbutyrate in a male adolescent with bile salt export pump deficiency disease 93
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods 93
DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods 93
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 93
null 92
Authors’ reply: Comment to “Liver transplantation for patients with alcoholic liver disease: An open question” 91
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 91
Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice 91
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. 90
Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study 90
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 90
Update on Alcohol and Viral Hepatitis 89
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 89
Gamma-hydroxybutyric acid plus naltrexone in the treatment of alcoholics resistant to monotherapy. 88
Stem cell mobilization and collection in patients with liver cirrhosis. 88
Stem cell therapy for human liver cirrhosis: a cautious analysis of the results 88
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. 88
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 88
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 87
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort 87
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 87
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 87
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 86
Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: A systematic review and meta-analysis 86
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 86
Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a 85
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 85
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 85
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 85
Totale 10565
Categoria #
all - tutte 27776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27776

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018523 0003 40 217 2046926
2018/20191748 4324027164 24217 9894 140258140303
2019/20207845 106618873445 814969 10051014 1074482262453
2020/20213758 782305133125 71157 64220 3262141781183
2021/20225352 507182368459 466303 90345 1923721221847
2022/20231747 61980027553 00 00 0000
Totale 21137